Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2012-07-11

Clinical Trial Update: Safety and Efficacy Study of Catumaxomab to Treat Ovarian Cancer After a Complete Response to Chemotherapy [Phase 2]

View source ↗

Summary

Phase 2 safety and efficacy study of catumaxomab for ovarian cancer after a complete response to chemotherapy has completed, with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Catumaxomab (Catumaxomab)

Snippet

Sponsor: Neovii Biotech | Conditions: Ovarian Cancer | Phase 2 | Status: COMPLETED | Results posted: 2012-07-11